Bondex All Purpose Joint Cement / SX Joint Cement / SX Topping Cement / Bondex Ready-Mixed Joint Cement

Product Description

Bondex All Purpose Joint Cement, SX Joint Cement, SX Topping Cement, and Bondex Ready-Mixed Joint Cement were a family of drywall finishing products manufactured and sold under the Bondex brand name from approximately 1961 through 1977. These products were formulated for use in the finishing and taping stages of interior drywall installation, serving as the bonding and smoothing compounds applied over wallboard seams, nail heads, corner beads, and other surface imperfections before final painting or decoration.

Joint compounds of this era were workhorses of the construction industry. Bondex’s product line was marketed to professional tradespeople and general contractors performing residential, commercial, and industrial construction. The ready-mixed formulations were especially convenient, arriving in pre-blended form that required little preparation before application. The topping and all-purpose variants addressed different stages of the multi-coat drywall finishing process, from initial tape embedding through final skim coats intended to produce a smooth, paint-ready wall surface.

Bondex products were distributed broadly across the United States during the period of manufacture. Their presence on construction job sites — spanning new home developments, commercial office buildings, industrial facilities, and institutional construction — was widespread. The brand name was sufficiently recognized that Bondex joint compounds appeared in trade catalogs and building supply inventories throughout the 1960s and into the mid-1970s.

Asbestos Content

Bondex All Purpose Joint Cement and the related SX and Ready-Mixed formulations contained chrysotile asbestos as an ingredient during their production years of 1961 through 1977. Chrysotile, a member of the serpentine mineral group, was the dominant form of asbestos used commercially in the United States during this period and was incorporated into joint compounds for its functional properties.

In drywall finishing applications, chrysotile asbestos contributed to the workability and performance characteristics of the compound. The fibrous mineral structure helped bind the mixture, improved the product’s resistance to cracking as it dried and cured, and added tensile reinforcement to the hardened film. These properties made asbestos an attractive additive for manufacturers competing in a demanding construction materials market.

The presence of chrysotile in joint compound formulations was not unique to Bondex. Numerous manufacturers incorporated asbestos into similar products during this era. However, the specific inclusion of chrysotile in Bondex’s product line has been documented through litigation and product testing, establishing that workers who used these products were potentially exposed to asbestos fibers released during normal application activities.

How Workers Were Exposed

Exposure to asbestos from Bondex joint cement products occurred primarily through the dust generated during the handling, mixing, application, and finishing of the compounds. Industrial workers and construction tradespeople who worked with or near these products faced multiple pathways of potential fiber release.

Dry mixing activities created significant dust clouds. When workers combined powdered joint compound formulations with water, or when dry product was poured from bags and containers, airborne asbestos fibers could be released into the breathing zone of the worker performing the task and those nearby.

Sanding was among the most hazardous activities associated with joint compound use. After compound dried between coats, workers sanded the hardened material to achieve smooth, uniform surfaces. Dry sanding of asbestos-containing joint compound is well-documented as generating substantial quantities of fine respirable dust, including asbestos fibers, that could remain suspended in the air for extended periods. Workers performing this task without adequate respiratory protection could inhale significant quantities of fiber.

Application activities — spreading compound with taping knives, feathering edges, and skimming coats — also generated dust and could release fibers, particularly in enclosed or poorly ventilated spaces where airborne particles could accumulate. Workers who were present on job sites where joint compound was being sanded or applied, even if not directly performing those tasks, could experience bystander exposure.

Industrial workers in manufacturing facilities where these products were produced faced a separate occupational exposure profile, potentially encountering raw chrysotile fiber and compound ingredients prior to formulation and packaging.

The cumulative exposure experienced by professional drywall finishers, tapers, and construction workers who used Bondex products across multiple projects over working careers represented a significant concern. Asbestos-related diseases, including mesothelioma, lung cancer, asbestosis, and pleural disease, are associated with repeated or prolonged inhalation of asbestos fibers, and the latency period for these diseases can span decades from initial exposure.

Documented Trust Fund / Legal Options

Bondex joint cement products fall under Tier 2 litigation status. There is no established asbestos bankruptcy trust fund associated with the Bondex brand or its manufacturer that currently accepts claims related to these products. Individuals seeking compensation for asbestos-related illness connected to Bondex All Purpose Joint Cement, SX Joint Cement, SX Topping Cement, or Bondex Ready-Mixed Joint Cement must pursue remedies through civil litigation in the tort system.

Litigation records document that plaintiffs have brought claims against manufacturers, distributors, and sellers of asbestos-containing joint compound products, including Bondex formulations, alleging that exposure to chrysotile asbestos fibers released during use of these products caused serious and fatal diseases. Plaintiffs alleged that defendants knew or should have known of the hazards associated with asbestos exposure and failed to adequately warn workers of those risks. Litigation records further document claims that the marketing and distribution of asbestos-containing joint compounds without adequate safety warnings or instructions for protective use contributed to preventable occupational disease.

Workers diagnosed with mesothelioma, lung cancer, asbestosis, or other asbestos-related conditions who have documented occupational contact with Bondex joint compound products during the 1961–1977 production period may have grounds for civil claims. The ability to pursue such claims depends on applicable statutes of limitations, which in many jurisdictions begin to run from the date of diagnosis rather than the date of exposure, and varies by state.

Individuals and surviving family members are encouraged to consult with an attorney experienced in asbestos litigation to evaluate potential claims. Legal counsel can assist in gathering employment records, product identification evidence, and medical documentation necessary to establish the link between Bondex product exposure and a confirmed asbestos-related diagnosis. Given that multiple manufacturers produced asbestos-containing joint compounds during the same period, an attorney may also identify additional responsible parties beyond the Bondex manufacturer.